MoonLake Immunotherapeutics – NASDAQ:MLTX

Add to watchlist

$52.66

-2.71

-4.89%

Market closed

Open in 1 day

+19.33%

month

+19.33%

quarter

-12.14%

year

Market Cap	3.25B
Enterprise value	774.94M

P/E	-12.05
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	16.65
PEG ratio	N/A
EPS	-0.75

Revenue	N/A
EBITDA	-60.97M
Income	-40.67M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

MoonLake Immunotherapeutics (NASDAQ:MLTX): Profit margin
Jun 2023	0	-10.13M
Sep 2023	0	-9.42M
Dec 2023	19.73K	-7.43M	-37678.97%
Mar 2024	0	-13.67M

MoonLake Immunotherapeutics Financials Estimate

Q Y

MoonLake Immunotherapeutics (NASDAQ:MLTX): Analyst Estimates
Mar 2024	0	-13.67M
Sep 2025	19.73K	-43.73M	-221591.1%
Oct 2025	0	-40.08M
Dec 2025	0	-39.14M

Analysts Price target
Financials & Ratios estimates

MoonLake Immunotherapeutics (NASDAQ:MLTX): Debt to assets
Jun 2023	506621195	7.51M	1.48%
Sep 2023	500218686	10.57M	2.11%
Dec 2023	526540115	13.04M	2.48%
Mar 2024	564117138	11.73M	2.08%

MoonLake Immunotherapeutics (NASDAQ:MLTX): Cash Flow
Jun 2023	-12.15M	12.67M	451.28M
Sep 2023	-9.25M	-174.37M	0
Dec 2023	-12.34M	116.86M	28.41M
Mar 2024	-14.94M	-28.80M	50.97M

MoonLake Immunotherapeutics alternative data

MoonLake Immunotherapeutics
Employees

MoonLake Immunotherapeutics (NASDAQ:MLTX): Employee count
Aug 2023	20
Sep 2023	20
Oct 2023	20
Nov 2023	20
Dec 2023	20
Jan 2024	20
Feb 2024	20
Mar 2024	50
Apr 2024	50
May 2024	50
Jun 2024	50
Jul 2024	50

MoonLake Immunotherapeutics
Hedge Funds Holdings Q1 2023

8.77% -91.23%

of MLTX is owned by hedge funds

14 -19

hedge funds hold MLTX stock

2.57M -35.17M

shares is hold by hedge funds

MLTX hedge funds holdings changes

MoonLake Immunotherapeutics
Insider Trading

MoonLake Immunotherapeutics (NASDAQ:MLTX): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	827100	0
Jun 2023	1250000	0
Oct 2023	352051	0
Dec 2023	0	100000
Feb 2024	0	384740

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	29 Feb 2024	SANTOS DA SILVA JORGE director, officer: Chief Executive O.. director, officer: Chief Execut..	Class A ordinary shares, par value $0.0001 per share	4,740	$55.89	$264,919
Sale	28 Feb 2024	SANTOS DA SILVA JORGE director, officer: Chief Executive O.. director, officer: Chief Execut..	Class A ordinary shares, par value $0.0001 per share	56,065	$55	$3,083,575
Sale	28 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	31,910	$55	$1,755,050
Sale	28 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	28,090	$55	$1,544,950
Sale	27 Feb 2024	SANTOS DA SILVA JORGE director, officer: Chief Executive O.. director, officer: Chief Execut..	Class A ordinary shares, par value $0.0001 per share	62,810	$55	$3,454,550
Sale	27 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	29,491	$55	$1,622,005
Sale	27 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	29,431	$55	$1,618,705
Sale	21 Feb 2024	SANTOS DA SILVA JORGE director, officer: Chief Executive O.. director, officer: Chief Execut..	Class A ordinary shares, par value $0.0001 per share	1,125	$55.27	$62,179
Sale	21 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	509	$55.31	$28,153
Sale	21 Feb 2024	REICH KRISTIAN officer: Chief Scientific Officer officer: Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	569	$55.3	$31,466

MLTX insider trading transactions

MoonLake Immunotherapeutics
Latest News

Monday, 9 September 2024
07:00	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11	globenewswire.com
Thursday, 18 July 2024
14:19	MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward	seekingalpha.com
Thursday, 16 May 2024
08:00	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa	globenewswire.com
Sunday, 12 May 2024
08:37	MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion	Seeking Alpha
Monday, 4 March 2024
08:00	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	GlobeNewsWire
Monday, 12 February 2024
18:01	The 7 Best Momentum Stocks You Can Purchase Today	InvestorPlace
Wednesday, 10 January 2024
09:46	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?	Zacks Investment Research
Saturday, 9 December 2023
06:38	MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment	Seeking Alpha
Monday, 6 November 2023
11:59	MoonLake Immunotherapeutics stock craters after arthritis treatment study disappoints	Proactive Investors
Wednesday, 27 September 2023
21:24	7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio	InvestorPlace
20:00	MoonLake Immunotherapeutics Is Now Thoroughly De-Risked	Seeking Alpha
Tuesday, 12 September 2023
11:40	Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday	The Motley Fool
Thursday, 31 August 2023
08:30	The 7 Most Promising Momentum Stocks to Own Now	InvestorPlace
Sunday, 27 August 2023
23:54	Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)	Seeking Alpha
Monday, 31 July 2023
14:43	August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge	Seeking Alpha
Monday, 24 July 2023
14:45	Strong Mid-Cap Insider Buys: Q2 2023	Seeking Alpha
Friday, 14 July 2023
15:38	Exclusive: MoonLake Immunotherapeutics explores sale-sources	Reuters
Thursday, 29 June 2023
14:41	Why MoonLake Immunotherapeutics Stock Skyrocketed This Week	The Motley Fool
Wednesday, 28 June 2023
09:06	MoonLake Immunotherapeutics Makes a Moonshot on Trials	MarketBeat
Tuesday, 27 June 2023
18:56	Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today	The Motley Fool
Monday, 26 June 2023
14:36	Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday	The Motley Fool
09:41	Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today?	InvestorPlace
Friday, 26 May 2023
10:05	MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why	Zacks Investment Research
Thursday, 11 May 2023
09:56	Why MoonLake (MLTX) Might Surprise This Earnings Season	Zacks Investment Research
Monday, 24 April 2023
09:53	MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable	Zacks Investment Research
Wednesday, 5 April 2023
13:42	What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock	Zacks Investment Research
Tuesday, 31 May 2022
16:51	Why MoonLake Immunotherapeutics Stock Shot Up 41.1% on Tuesday	The Motley Fool
09:24	Why MoonLake Immunotherapeutics Shares Are Surging Higher Today	Benzinga

Frequently Asked Questions (FAQ)

What's the price of MoonLake Immunotherapeutics stock today?

One share of MoonLake Immunotherapeutics stock can currently be purchased for approximately $52.66.
When is MoonLake Immunotherapeutics's next earnings date?

Unfortunately, MoonLake Immunotherapeutics's (MLTX) next earnings date is currently unknown.
Does MoonLake Immunotherapeutics pay dividends?

No, MoonLake Immunotherapeutics does not pay dividends.
How much money does MoonLake Immunotherapeutics make?

MoonLake Immunotherapeutics has a market capitalization of 3.25B.
What is MoonLake Immunotherapeutics's stock symbol?

MoonLake Immunotherapeutics is traded on the NASDAQ under the ticker symbol "MLTX".
What is MoonLake Immunotherapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of MoonLake Immunotherapeutics?

Shares of MoonLake Immunotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does MoonLake Immunotherapeutics have?

As Jul 2024, MoonLake Immunotherapeutics employs 50 workers.
When MoonLake Immunotherapeutics went public?

MoonLake Immunotherapeutics is publicly traded company for more then 4 years since IPO on 20 Oct 2020.
What is MoonLake Immunotherapeutics's official website?

The official website for MoonLake Immunotherapeutics is moonlaketx.com.
How can i contact MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics can be reached via phone at +41 41 510 80 22.

MoonLake Immunotherapeutics

moonlaketx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

+41 41 510 80 22

Dorfstrasse 29
Zug, 6300

CIK: 0001821586
ISIN: KY61559X1045
CUSIP: 61559X104